Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial
Open accessAbstract
Discontinuing denosumab is associated with bone loss and possibly increased fracture risk. We investigated if treatment with zoledronate (ZOL) could prevent bone loss and if the timing of the ZOL infusion influenced the outcome. We report on a 2-year randomized, open label, interventional study including 61 patients with osteopenia, discontinuing denosumab after 4.6 ± 1.6 years. We administrated ZOL 6 months (6M group, n = 20) or 9 months (9M group, n = 20) after the last denosumab injection or when bone turnover had increased (OBS group, n = 21). We monitored the patients with DXA and bone turnover markers. Our primary endpoints were change in lumbar spine BMD (LSBMD) 6 months after ZOL and the proportion of patients who failed to maintain BMD. The study is ongoing (clinicaltrials.gov; NCT03087851). We included 61 participants and 59 patients completed follow-up 12 months after ZOL. Six months after ZOL, LSBMD had decreased significantly by (mean ± SE) 2.1% ± 0.9%, 4.3% ± 1.1%, and 3.0% ± 1.1% in the 6M, 9M, and OBS groups, respectively, and by 4.8% ± 0.7%, 4.1% ± 1.1%, and 4.7% ± 1.2% 12 months after ZOL in the 6M, 9M, and OBS groups, respectively (p < .02, no between-group differences). BMD loss above the least significant change was seen in all groups; at the spine: 6M, n = 6 (30%); 9M, n = 9 (45%); and OBS, n = 9 (47%); and at the total hip: 6M, n = 1 (5%); 9M, n = 5 (25%); and OBS, n = 2 (11%). In the 6M group p-crosslinked C-terminal telopeptide (p-CTX) decreased initially, but increased rapidly thereafter, and 6 months after ZOL, p-CTX was 0.60 ± 0.08 g/L. p-CTX increased rapidly in the 9M and OBS groups, was suppressed by ZOL but increased again thereafter; p-CTX was 0.47 ± 0.05 μg/L and 0.47 ± 0.05 μg/L in the 9M and OBS groups 6 months after ZOL, respectively. Incident vertebral fractures were seen in two women in the 9M group. Treatment with ZOL irrespective of the timing did not fully prevent loss of BMD in patients discontinuing denosumab. © 2020 American Society for Bone and Mineral Research.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The rebound effect after DMAB discontinuation is not fully inhibited by bisphosphonate therapy.
“This rebound effect is not fully inhibited by bisphosphonate therapy,261 probably because osteomorphs first accumulate at bone sites and are thus not accessible to potent bisphosphonate treatment.”
From Bone remodeling: an operational process ensuring survival and bone mechanical competence (2022) · cites this paper as [261]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996 · see citing works
Cummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N. L., Jensen, J. B., McClung, M. R., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 742 · see citing works
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700 · see citing works
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martín, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 692 · see citing works
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y., Grazette, L. P., Martín, J. S., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 625 · see citing works
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & Martín, J. S. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 579 · see citing works
Anastasilakis, A. D., Pοlyzos, S. A., Makras, P., Aubry‐Rozier, B., Kaouri, S., & Lamy, O. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3110 · Cited by 375 · see citing works
on behalf of the DAPS Investigators, Freemantle, N., Satram‐Hoang, S., Tang, E., Kaur, P. P., Macarios, D., Siddhanti, S. R., Borenstein, J. E., & Kendler, D. L. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1780-1 · Cited by 289 · see citing works
Anastasilakis, A. D., Papapoulos, S. E., Pοlyzos, S. A., Appelman‐Dijkstra, N. M., & Makras, P. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3853 · Cited by 165 · see citing works
Popp, A. W., Zysset, P. K., & Lippuner, K. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3458-6 · Cited by 159 · see citing works
Bone Mineral Density After Transitioning From Denosumab to Alendronate
Kendler, D. L., Chines, A. A., Clark, P., Ebeling, P. R., McClung, M. R., Rhee, Y., Huang, S., & Stad, R. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz095 · Cited by 121 · see citing works
Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Reid, I. R., Horne, A. M., Mihov, B., & Gamble, G. D. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0288-x · Cited by 119 · see citing works
Ferrari, S., Libanati, C. R., Lin, C. J. F., Brown, J. P., Cosman, F., Czerwinski, E. J., de Gregorio, L. H., Malouf, J., Reginster, J.-Y., Wang, A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3722 · Cited by 113 · see citing works
Everts‐Graber, J., Reichenbach, S., Ziswiler, H. R., Studer, U., & Lehmann, T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3962 · Cited by 100 · see citing works
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
Horne, A. M., Mihov, B., & Reid, I. R. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0404-6 · Cited by 95 · see citing works
Anastasilakis, A. D., Yavropoulou, M. P., Makras, P., Sakellariou, G. T., Papadopoulou, F. G., Gerou, S., & Papapoulos, S. E. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1027 · Cited by 88 · see citing works
Rosiglitazone Decreases Bone Mass and Bone Marrow Fat
Harsløf, T., Wamberg, L., Møller, L. F., Stødkilde‐Jørgensen, H., Ringgaard, S., Pedersen, S. B., & Langdahl, B. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2077 · Cited by 58 · see citing works
Self-citationPossible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
Lehmann, T., & Aeberli, D. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4108-y · Cited by 54 · see citing works
Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up
Horne, A. M., Mihov, B., & Reid, I. R. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00553-w · Cited by 25 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Eastell R, Vittinghoff E, Lui LY, et al. Surrogate threshold effect: a novel approach for potential approval of new osteoporosis treatments using change in BMD. Study-level analysis from the FNIH Bone Qual- ity Project. J Bone Miner Res. 2019;32 Suppl 1. [Presented orally at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2019 Sep 20-23; Orlando, FL, USA; Presentation Number: 1090]. Available from: https://www.asbmr.org/education/Abstract Detail?aid=a68865ec-0073-4624-8a7c-c3f93f10efa3. Journal of Bone and Mineral Research n 1870 SØLLING ET AL. 15234681, 2020, 10, Downloaded from https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4098, Wiley Online Library on [14/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
Cited by
Sorted by citations
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593 · see citing works
Bone remodeling: an operational process ensuring survival and bone mechanical competence
Bolamperti, S., Villa, I., & Rubinacci, A. (2022) · Bone Research · doi:10.1038/s41413-022-00219-8 · Cited by 482 · see citing works
Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis
Ramchand, S. K., & Leder, B. Z. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad496 · Cited by 86 · see citing works
- Authors
- Sølling, A. S., Harsløf, T., & Langdahl, B.
- Affiliations
- Aarhus University Hospital (DK)
- Corresponding author
- Sølling, Anne Sophie
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-27
- Volume
- 35
- Issue
- 10
- Pages
- 1858-1870
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W3030624497
- Cited by
- 111
- References
- 19
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 15 · 2023: 15 · 2022: 20 · 2021: 19 · 2020: 9
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Aarhus Universitet
- Amgen Foundation
- Ekspeditionssekretær Cand.Jur. Torkil Steenbecks Legat
- P. Carl Petersen’s Foundation
- The Danish Osteoporosis Society
- Vilhelm Pedersen and wife’s Foundation
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- zoledronic acid, denosumab discontinuation, osteoporosis, osteopenia, bone loss, bone turnover markers, C-terminal telopeptide, lumbar spine bone mineral density, fracture risk, RANKL inhibition, bone resorption inhibition, RANKL antibodies
- MeSH terms
- Denosumab, Zoledronic Acid, Diphosphonates, Humans, Osteoporosis, Bone Density, Bone Remodeling, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
